HIV-1 uses one of two coreceptors for entry into cells: CCR5 and CXCR4. CCR5 inhibitors, block the CCR5 receptor, but not the CXCR4 coreceptor, reducing viral entry, replication and therefore plasma viral load. CCR5 inhibitors, of which maraviroc is the only one licensed, are only effective if a patient’s HIV uses CCR5 as its coreceptor.[34] …
Genotypic determination of HIV-1 CCR5/CXCR4 tropism Read More »
Abacavir hypersensitivity reaction (AHSR) affects 4-8% of patients with HIV-1 infection within the first 6 weeks of starting abacavir. It is usually characterised by fever, rash, abdominal pains and lethargy. Symptoms related to abacavir hypersensitivity reaction deteriorate with continued therapy and improve within 72 hours of abacavir discontinuation. Rechallenging with abacavir after a hypersensitivity reaction …
Silvester C, Healey DS, Cunningham P, Dax EM. Multisite evaluation of four anti-HIV-1/HIV-2 enzyme immunoassays. Australian HIV Test Evaluation Group. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:411-9. Branson BM and Stekler JD Detection of Acute HIV Infection: We Can’t Close the Window. editorial commentary JID 2012;205:521 Stekler J, Maenza J, Stevens CE, Swenson PD: …
Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce
Acknowledgement of Country
We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.
ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM